Contract Services Clinical Research
8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026
Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...
July 29, 2026 | Analysis
AsymBio Breaks Ground on Shanghai R&D Hub to Accelerate Biologics Development
AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.S...
July 29, 2026 | News
AnHorn Medicines Advances First-in-Class AH-008 into Phase I Trial for Chemotherapy-Induced Neuropathy Prevention
AnHorn Medicines announced the successful completion of the first subject first dose in the Phase I clinical trial of AH-008, a first-in-class neuroprotect...
July 27, 2026 | News
ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406
Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial w...
July 27, 2026 | News
Ribo’s Vortosiran Achieves 92% FXI Activity Reduction in Phase 2a Coronary Artery Disease Study
Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at C...
July 24, 2026 | News
Tikva Allocell Raises $8M Series A to Advance Off-the-Shelf CAR-T Therapy for Solid Tumours
Funding will support completion of IND-enabling activities and planned year-end IND submission for TAVST01, Tikva's lead off-the-shelf CAR-T candidate targ...
July 24, 2026 | News
Nona Biosciences Partners with MedUni Vienna to Advance Fully Human Antibody Research
Partnership grants Ignaz Semmelweis Institute access to Nona's H2L2 Harbour Mice® transgenic mouse technology platform for translational antibody ...
July 24, 2026 | News
GHIT Fund Invests JPY 140M to Accelerate Portable Rapid Diagnostic System for Ebola
The Global Health Innovative Technology (GHIT) Fund announced an investment of JPY 140 million (approximately USD 862,000) in a project to develop a portab...
July 24, 2026 | News
Alebund Doses First Participant in Global Phase IIb Trial of AP306 for Hyperphosphatemia
Alebund Pharmaceuticals a renal-focused biopharmaceutical company, announced that the first participant has been randomized and dosed in the global Phase I...
July 23, 2026 | News
China Approves SystImmune’s Iza-bren for Recurrent or Metastatic Esophageal Cancer
SystImmune Inc. announced that its parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), has received regulatory approval from China's Na...
July 21, 2026 | News
Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027
250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...
July 20, 2026 | News
Merck Invests €25M to Expand BioReliance Testing Capabilities in Europe
• New 2,000-square-meter facility expands Merck’s global testing network with commercial drug substance and drug product release testing a...
July 17, 2026 | News
Australia Builds a New Radiopharmaceutical Gateway from Research to Patient Care
First-of-its-kind facility in Australia where radiopharmaceuticals are developed, manufactured and administered to patients under one roof. Patient care...
July 17, 2026 | News
BioArctic and Eisai Secure FDA Approval for At-Home Leqembi Injection to Treat Early Alzheimer's Disease
BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced that the US Food and Drug Administration (FDA) has approved a supplement...
July 15, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
